Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma

Clinical Proteomics

Nikhat Ahmed³  M Ataur Rahman²  Abid Azhar²  Atta M Nawabi¹  A-Bashar Abdul Karim¹  Jameson Forster¹  Yu-Jui Yvonne Wan¹  Saadia Zahid³  Rizma Khan³ 

[1] The University of Kansas Medical Center, Kansas City Lawrence, Kansas, USA;The Karachi Institute of Biotechnology and Genetic Engineering, (KIBGE), University of Karachi, Karachi, Pakistan;Neurochemistry Research Unit Laboratory, Department of Biochemistry, University of Karachi, Karachi, Pakistan

关键词: ESI-Q-TOF MS/MS mass spectrometry;    Proteomics;    S-nitrosylation;    Two dimensional gel electrophoresis;    Cytochrome b5A;    Hepatocellular carcinoma;   

Others  :  1026344
DOI  :  10.1186/1559-0275-10-6

 received in 2012-09-17, accepted in 2013-05-24,  发布年份 2013

【 摘 要 】

Background

Complex molecular events lead to development and progression of liver cirrhosis to HCC. Differentially expressed nuclear membrane associated proteins are responsible for the functional and structural alteration during the progression from cirrhosis to carcinoma. Although alterations/ post translational modifications in protein expression have been extensively quantified, complementary analysis of nuclear membrane proteome changes have been limited. Deciphering the molecular mechanism that differentiate between normal and disease state may lead to identification of biomarkers for carcinoma.

Results

Many proteins displayed differential expression when nuclear membrane proteome of hepatocellular carcinoma (HCC), fibrotic liver, and HepG2 cell line were assessed using 2-DE and ESI-Q-TOF MS/MS. From the down regulated set in HCC, we have identified for the first time a 15 KDa cytochrome b5A (CYB5A), ATP synthase subunit delta (ATPD) and Hemoglobin subunit beta (HBB) with 11, 5 and 22 peptide matches respectively. Furthermore, nitrosylation studies with S-nitrosocysteine followed by immunoblotting with anti SNO-cysteine demonstrated a novel and biologically relevant post translational modification of thiols of CYB5A in HCC specimens only. Immunofluorescence images demonstrated increased protein S-nitrosylation signals in the tumor cells and fibrotic region of HCC tissues. The two other nuclear membrane proteins which were only found to be nitrosylated in case of HCC were up regulated ATP synthase subunit beta (ATPB) and down regulated HBB. The decrease in expression of CYB5A in HCC suggests their possible role in disease progression. Further insight of the functional association of the identified proteins was obtained through KEGG/ REACTOME pathway analysis databases. String 8.3 interaction network shows strong interactions with proteins at high confidence score, which is helpful in characterization of functional abnormalities that may be a causative factor of liver pathology.

Conclusion

These findings may have broader implications for understanding the mechanism of development of carcinoma. However, large scale studies will be required for further verification of their critical role in development and progression of HCC.

【 授权许可】

   
2013 Khan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
• [2]Okuda K: Hepatocellular carcinoma. J Hepatol 2000, 32:225-237.
• [3]El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
• [4]Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH: Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994, 19:222-226.
• [5]Marquardt JU, Galle PR, Teufel A: Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy. Dtsch Med Wochenschr 2012, 137:855-860.
• [6]el Tazi M, Essadi I, M'rabti H, Touyar A, Errihani PH: Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci 2011, 3:167-175.
• [7]Dumpis U, Kovalova Z, Jansons J, Cupane L, Sominskaya I, Michailova M, Karayiannis P, Gardovska D, Viazov S, Ross S, Roggendorf M, Pumpens P: An outbreak of HBV and HCV infection in a paediatric oncology ward: epidemiological investigations and prevention of further spread. J Med Virol 2003, 69:331-338.
• [8]Seow TK, Liang RC, Leow CK, Chung MC: Hepatocellular carcinoma: from bedside to proteomics. Proteomics 2001, 1:1249-1263.
• [9]Shin BK, Hong W, Hanash S: Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:407-413.
• [10]Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W: The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int 2012, 32:1053-1063.
• [11]Steel LF, Mattu TS, Mehta A, Hebestreit H, Dwek R, Evans AA, London WT, Block T: A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis Markers 2001, 17:179-189.
• [12]Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-1097.
• [13]Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF 3rd, Zhao Y: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002, 1:117-124.
• [14]Mínguez B, Lachenmayer A: Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Marker 2011, 31:181-190.
• [15]Chan DW, Colantonio DA: Clinical proteomics:cancer diagnostics? J Clin Ligand Assay 2005, 28:35-37.
• [16]Zhang Z, Chan DW: Cancer proteomics:in pursuit of “true” biomarker discovery. (Editorial). cancer epidemiol. Biomark Prevent 2005, 14:2283-2286.
• [17]Song Y, Hao Y, Sun A, Li T, Li W, Guo L, Yan Y, Geng C, Chen N, Zhong F, Wei H, Jiang Y, He F: Sample preparation project for the subcellular proteome of mouse liver. Proteomics 2006, 6:5269-5277.
• [18]Lee TY, Chen YJ, Lu TC, Huang HD, Chen YJ: SNOSite: exploiting maximal dependence decomposition to identify cysteine S-nitrosylation with substrate site specificity. PLoSOne 2011, 6:e21849.
• [19]Majano PL, García-Monzón C, López-Cabrera M, Lara-Pezzi E, Fernández-Ruiz E, García-Iglesias C, Borque MJ, Moreno-Otero R: Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 1998, 101:1343-1352.
• [20]Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus- positive cases. Clin Cancer Res 2001, 7:1325-1332.
• [21]Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, Hohler T, Galle PR, Phillips DH, Markin R, Marrogi AJ, Harris CC: Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci USA 2000, 97:12770-12775.
• [22]Bogdan C: Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
• [23]Gaston B, Singel D, Doctor A, Stamler JS: S -nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med 2006, 173:1186-1193.
• [24]Foster MW, Hess DT, Stamler JS: Protein S - nitrosylation in health and disease: a current perspective. Trends Mol Med 2009, 15:391-404.
• [25]Wei W, Li B, Hanes MA, Kakar S, Chen X, Liu L: S -nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med 2010, 2(19):19ra13.
• [26]Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS: Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005, 6:150-166.
• [27]Liu L, Xu-Welliver M, Kanugula S, Pegg AE: Inactivation and degradation of O(6)-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Res 2002, 62:3037-3043.
• [28]Fukumura D, Kashiwagi S, Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer 2006, 6:521-534.
• [29]Pedrazzini E, Villa A, Longhi R, Bulbarelli A, Borgese N: Mechanism of residence of cytochrome b(5), a tail-anchored protein, in the endoplasmic reticulum. J Cell Biol 2000, 148:899-914.
• [30]Pandey AV, Miller WL: Regulation of 17, 20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17. J Biol Chem 2005, 280:13265-13271.
• [31]Stringer RA, Strain-Damerell C, Nicklin P, Houston JB: Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 2009, 37:1025-1034.
• [32]Schenkman JB, Jansson I: The many roles of cytochrome b5. Pharmacol Ther 2003, 97:139-152.
• [33]Porter TD: The roles of cytochrome b5 in cytochrome P450 reactions. J Biochem Mol Toxicol 2002, 16:311-316.
• [34]Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T: Roles of nadph-p450 reductase and apo- and holo-cytochrome b5 on xenobiotics oxidations catalyzed by 12 recombinant human cytochrome p450s expressed in membranes of Escherichia coli. Protein Expr Purif 2002, 24:329-337.
• [35]Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011, 32:81-151.
• [36]Blanc M, Hsieh WY, Robertson KA, Watterson S, Shui G, Lacaze P, Khondoker M, Dickinson P, Sing G, RodrÃguez-MartÃn S, Phelan P, Forster T, Strobl B, Muller M, Riemersma R, Osborne T, Wenk MR, Angulo A, Ghazal P: Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol 2011, 9:e1000598.
• [37]Finn RD, McLaughlin LA, Hughes C, Song C, Henderson CJ, RolandWolf C: Cytochrome b null mouse: a new model for studying inherited skin disorders and the role of unsaturated fattyacids in normal homeostasis. Transgenic Res 2011, 20:491-502.
• [38]Abe K, Kimura S, Kizawa R, Anan FK, Sugita Y: Amino acid sequences of cytochrome b5 from human, porcine, and bovine erythrocytes and comparison with liver microsomal cytochrome b5. J Biochem 1985, 97:1659-1668.
• [39]Takematsu H, Kawano T, Koyama S, Kozutsumi Y, Suzuki A, Kawasaki T: Reaction mechanism underlying CMP-N-acetylneuraminic acid hydroxylation in mouse liver: formation of a ternary complex of cytochrome b5, CMP-N-acetylneuraminic acid, and a hydroxylation enzyme. J Biochem 1994, 115:381-386.
• [40]Guiard B, Groudinsky O, Lederer F: Homology between bakers’ yeast cytochrome b2 and liver microsomal cytochrome b5. Proc Natl Acad Sci USA 1974, 71:2539-2543.
• [41]Guiard B, Lederer F: The “b5-like” domain from chicken- liver sulfite oxidase: a new case of common ancestral origin with liver cytochrome b5 and bakers’ yeast cytochrome b5 core. Eur J Biochem 1977, 74:181-190.
• [42]Yantsevich AV, Gilep AA, Usanov SA: Mechanism of electron transfer in fusion protein cytochrome b5–NADH_cytochrome b5 reductase. Biochemistry (Mosc) 2008, 73:1096-1107.
• [43]Dunn TM, Haak D, Monaghan E, Beeler TJ: Synthesis of monohydroxylated inositolphosphorylceramide (IPC-C) in Saccharomyces cerevisiae requires Scs7p, a protein with both a cytochrome b5-like domain and a hydroxylase/desaturase domain. Yeast 1998, 14:311-321.
• [44]Wai PY, Kuo PC: Intersecting pathways in inflammation and cancer: Hepatocellular carcinoma as a paradigm. World J Clin Oncol 2012, 3:15-23.
• [45]Hanash SM: Biomedical applications of two dimensional electrophoresis using immobilized pH gradients: Current status. Electrophoresis 2000, 21:1202-1209.
• [46]Reymond MA, Sanchez JC, Hughes GJ, Günther K, Riese J, Tortola S, Peinado MA, Kirchner T, Hohenberger W, Hochstrasser DF, Köckerling F: Standardized characterization of gene expression in human colorectal epithelium by two dimensional electrophoresis. Electrophoresis 1997, 18:842-848.
• [47]Keyes SR, Alfano JA, Jansson I, Cinti DL: Rat liver microsomal elongation of fattyacids. J Biochem 1979, 254:7778-7784.
• [48]Gan L, von Moltke LL, Trepanier LA, Harmatz JS, Greenblatt DJ, Court MH: Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. Drug Metab Dispos 2009, 37:90-96.
• [49]Lewis DF, Ito Y: Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin Drug Metab Toxicol 2008, 4:1181-1186.
• [50]Blum H, Beier H, Gross HJ: Silver staining of proteins in polyacrylamide gels. Electrophoresis 1987, 8:93-99.
• [51]Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
• [52]Asif AR, Oellerich M, Amstrong VW, Gross U, Reichard U: Analysis of the cellular Aspergillusfumigatus proteome that reacts with sera from rabbits developing an acquired immunity after experimental aspergillosis. Electrophoresis 2010, 31:1947-1958.
• [53]Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005, 33:741-748.
• [54]Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, Doerks T, Julien P, Roth A, Simonovic M, Bork P, von Mering C: STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:412-416.